117 related articles for article (PubMed ID: 11858907)
21. Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae.
Baum SE; Crawford SA; McElmeel ML; Whitney CG; Jorgensen JH
Antimicrob Agents Chemother; 2002 Sep; 46(9):3094-5. PubMed ID: 12183281
[TBL] [Abstract][Full Text] [Related]
22. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of
Choudhury S; Mun LK; Xuan ENC; Jia LS; Vasoo S; Wickramasinghe SS; Mee LJ
J Clin Pathol; 2019 Feb; 72(2):181-184. PubMed ID: 30446512
[TBL] [Abstract][Full Text] [Related]
24. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
Mutnick AH; Enne V; Jones RN
Ann Pharmacother; 2003 Jun; 37(6):769-74. PubMed ID: 12773059
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.
Cercenado E; García-Garrote F; Bouza E
J Antimicrob Chemother; 2001 Jan; 47(1):77-81. PubMed ID: 11152434
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait.
Al Sweih N; Mokaddas E; Jamal W; Phillips OA; Rotimi VO
J Chemother; 2005 Dec; 17(6):607-13. PubMed ID: 16433190
[TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
29. Activities of linezolid against rapidly growing mycobacteria.
Wallace RJ; Brown-Elliott BA; Ward SC; Crist CJ; Mann LB; Wilson RW
Antimicrob Agents Chemother; 2001 Mar; 45(3):764-7. PubMed ID: 11181357
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria.
Piper KE; Steckelberg JM; Patel R
J Infect Chemother; 2005 Aug; 11(4):207-9. PubMed ID: 16133715
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
Brown SD; Traczewski MM
Antimicrob Agents Chemother; 2010 May; 54(5):2063-9. PubMed ID: 20231392
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
34. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria.
Yagi BH; Zurenko GE
Anaerobe; 1997 Oct; 3(5):301-6. PubMed ID: 16887605
[TBL] [Abstract][Full Text] [Related]
36. Antibacterial activity of YC-20, a new oxazolidinone.
Cui Y; Dang Y; Yang Y; Zhang S; Ji R
J Antimicrob Chemother; 2006 Aug; 58(2):452-4. PubMed ID: 16807251
[TBL] [Abstract][Full Text] [Related]
37. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL
J Chemother; 2003 Apr; 15(2):113-7. PubMed ID: 12797385
[TBL] [Abstract][Full Text] [Related]
39. In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria.
Oh SH; Kim J; Baek SY; Chae SE; Park HS; Cho YL; Kwak JH
Molecules; 2017 Mar; 22(3):. PubMed ID: 28273820
[TBL] [Abstract][Full Text] [Related]
40. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
